Professor Laurence Zitvogel

Professor Laurence Zitvogel is a clinical oncologist and immunologist, and a full professor at Paris-Saclay University. After qualifying in medical oncology in 1992, she began her scientific career at the University of Pittsburgh (USA), where she specialised in both translational and fundamental immunology.

In 1998, she was appointed Director of Research at Inserm (U1015), and in 2020, became Scientific Director of the Clinicobiome programme at Gustave Roussy. Her work has played a key role in advancing cancer immunology and immunotherapy. With her team, she has pioneered several major concepts, including immunogenic cell death and the impact of the gut microbiota on cancer immunosurveillance and treatment response.

Her cutting-edge research has been recognised with numerous awards, including the INSERM Prize for Translational Research, the ASCO-SITC Award, the Brupbacher Prize (2017), the ESMO Immuno-Oncology Award (2017), the Baillet Latour Prize (2019), the Griffuel Prize (2019), the Duquesne Prize from the French Cancer League, and the German ITOC9 Award. In 2019, she was named an Officer of the Legion of Honour by the French Ministry of Health, and in 2021, she was elected to the French National Academy of Medicine.

Professor Zitvogel is among the world’s most cited scientists, according to Clarivate Analytics, appearing on the Highly Cited Researchers list since 2016. She has an h-index of 173, with over 599 publications listed on PubMed and more than 165,000 citations. She is also the scientific founder of the biotech company everImmune, dedicated to the clinical development of microbiota-based therapies in oncology.